Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono, PrecisionLife Ink Multi-Target R&D Collab
December 15, 2022
- Bribery Scandal Emerges for Hiroshima University Doctor over Ono’s Glactiv
December 14, 2022
- Takeda Puts Up US$4 Billion for Nimbus’ TYK2 Immune Therapy
December 14, 2022
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- NDA for Cefiderocol Accepted in Taiwan: Shionogi
December 14, 2022
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Enhertu Filed for HER2 Mutant Metastatic NSCLC: Daiichi Sankyo
December 14, 2022
- Daiichi Sankyo’s TROP2-Directed ADC Shows Promising Data for Triple Negative Breast Cancer
December 13, 2022
- Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
December 13, 2022
- RaQualia, DWTI Tie Up on Eye Disease Drug Research
December 13, 2022
- Minimum Age for Moderna Boosters Lowered to 12 Years Old in Japan
December 13, 2022
- Astellas CEO Vows Bold Investment in Targeted Protein Degradation to Fuel Drug Discovery
December 12, 2022
- Chugai, Towa Release Edirol’s Tablet Form in Japan
December 12, 2022
- Berinert SC Injection Holds Promise as “First Choice” for HAE Attacks: CSL Japan Chief
December 9, 2022
- CSL to Bring 1st Hemophilia B Gene Therapy to Japan Too; Eyes Riveted on Price Tag
December 9, 2022
- Merck CEO Wants to See Japan’s Shift to Pro-Innovation Structure in 2024 Reform
December 9, 2022
- Gilead to Take Over Yescarta Marketing Authorization in Japan
December 9, 2022
- UCB Files C5 Inhibitor Zilucoplan for Japan Approval
December 9, 2022
- Moderna CMO Hints at Filing Cancer Vaccine with PII Data, Topline Readout Soon
December 8, 2022
- Japan Ethical Drug Sales Up 1.8% in October: Crecon
December 8, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…